Literature DB >> 32886509

Catch and Anchor Approach To Combat Both Toxicity and Longevity of Botulinum Toxin A.

Lucy Lin, Margaret E Olson, Takashi Sugane, Lewis D Turner, Margarita A Tararina1, Alexander L Nielsen, Elbek K Kurbanov2, Sabine Pellett3, Eric A Johnson3, Seth M Cohen2, Karen N Allen4, Kim D Janda.   

Abstract

Botulinum neurotoxins have remarkable persistence (∼weeks to months in cells), outlasting the small-molecule inhibitors designed to target them. To address this disconnect, inhibitors bearing two pharmacophores-a zinc binding group and a Cys-reactive warhead-were designed to leverage both affinity and reactivity. A series of first-generation bifunctional inhibitors was achieved through structure-based inhibitor design. Through X-ray crystallography, engagement of both the catalytic Zn2+ and Cys165 was confirmed. A second-generation series improved on affinity by incorporating known reversible inhibitor pharmacophores; the mechanism was confirmed by exhaustive dialysis, mass spectrometry, and in vitro evaluation against the C165S mutant. Finally, a third-generation inhibitor was shown to have good cellular activity and low toxicity. In addition to our findings, an alternative method of modeling time-dependent inhibition that simplifies assay setup and allows comparison of inhibition models is discussed.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32886509      PMCID: PMC7581224          DOI: 10.1021/acs.jmedchem.0c01006

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  77 in total

1.  Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 A resolution.

Authors:  M A Hanson; R C Stevens
Journal:  Nat Struct Biol       Date:  2000-08

2.  Wound botulism associated with black tar heroin among injecting drug users.

Authors:  D J Passaro; S B Werner; J McGee; W R Mac Kenzie; D J Vugia
Journal:  JAMA       Date:  1998-03-18       Impact factor: 56.272

3.  Reexamining hydroxamate inhibitors of botulinum neurotoxin serotype A: extending towards the β-exosite.

Authors:  Garry R Smith; Dejan Caglič; Petr Capek; Yan Zhang; Sujata Godbole; Allen B Reitz; Tobin J Dickerson
Journal:  Bioorg Med Chem Lett       Date:  2012-04-11       Impact factor: 2.823

4.  Efficacy of certain quinolines as pharmacological antagonists in botulinum neurotoxin poisoning.

Authors:  S S Deshpande; R E Sheridan; M Adler
Journal:  Toxicon       Date:  1997-03       Impact factor: 3.033

5.  Novel Benzimidazole Inhibitors of Botulinum Neurotoxin/A Display Enzyme and Cell-Based Potency.

Authors:  Steven C Cardinale; Michelle M Butler; Gordon Ruthel; Jonathan E Nuss; Laura M Wanner; Bing Li; Ramdas Pai; Norton P Peet; Sina Bavari; Terry L Bowlin
Journal:  Botulinum J       Date:  2011

6.  Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E.

Authors:  C H Hatheway; J D Snyder; J E Seals; T A Edell; G E Lewis
Journal:  J Infect Dis       Date:  1984-09       Impact factor: 5.226

7.  New Steroidal 4-Aminoquinolines Antagonize Botulinum Neurotoxin Serotype A in Mouse Embryonic Stem Cell Derived Motor Neurons in Postintoxication Model.

Authors:  Jelena Konstantinović; Erkan Kiris; Krishna P Kota; Johanny Kugelman-Tonos; Milica Videnović; Lisa H Cazares; Nataša Terzić Jovanović; Tatjana Ž Verbić; Boban Andjelković; Allen J Duplantier; Sina Bavari; Bogdan A Šolaja
Journal:  J Med Chem       Date:  2018-02-06       Impact factor: 7.446

8.  Development of a fluorescence internal quenching correction factor to correct botulinum neurotoxin type A endopeptidase kinetics using SNAPtide.

Authors:  Thomas M Feltrup; Bal Ram Singh
Journal:  Anal Chem       Date:  2012-12-05       Impact factor: 6.986

9.  Identification of clinically viable quinolinol inhibitors of botulinum neurotoxin A light chain.

Authors:  Dejan Caglič; Michelle C Krutein; Kristin M Bompiani; Deborah J Barlow; Galit Benoni; Jeffrey C Pelletier; Allen B Reitz; Luke L Lairson; Karen L Houseknecht; Garry R Smith; Tobin J Dickerson
Journal:  J Med Chem       Date:  2014-01-15       Impact factor: 7.446

10.  Wound Botulism Outbreak Among Persons Who Use Black Tar Heroin - San Diego County, California, 2017-2018.

Authors:  Corey M Peak; Hilary Rosen; Amanda Kamali; Alyssa Poe; Mahtab Shahkarami; Akiko C Kimura; Seema Jain; Eric McDonald
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-01-04       Impact factor: 17.586

View more
  6 in total

1.  Use of Crystallography and Molecular Modeling for the Inhibition of the Botulinum Neurotoxin A Protease.

Authors:  Lewis D Turner; Alexander L Nielsen; Lucy Lin; Antonio J Campedelli; Nicholas R Silvaggi; Jason S Chen; Amanda E Wakefield; Karen N Allen; Kim D Janda
Journal:  ACS Med Chem Lett       Date:  2021-07-28       Impact factor: 4.632

2.  Identification of Slow-Binding Inhibitors of the BoNT/A Protease.

Authors:  Ealin N Patel; Lewis D Turner; Mark S Hixon; Kim D Janda
Journal:  ACS Med Chem Lett       Date:  2022-03-08       Impact factor: 4.632

3.  Identification of 3-hydroxy-1,2-dimethylpyridine-4(1H)-thione as a metal-binding motif for the inhibition of botulinum neurotoxin A.

Authors:  Lucy Lin; Lewis D Turner; Peter Šilhár; Sabine Pellett; Eric A Johnson; Kim D Janda
Journal:  RSC Med Chem       Date:  2020-11-12

4.  COVALENT INHIBITION OF BOTULINUM NEUROTOXIN A - EXPLORATION OF WARHEAD REACTIVITY AND FUNCTION USING A BIFUNCTIONAL APPROACH.

Authors:  Lewis D Turner; Alexander L Nielsen; Lucy Lin; Sabine Pellett; Takashi Sugane; Margaret E Olson; Kim D Janda
Journal:  Toxicon       Date:  2021-01-16       Impact factor: 3.033

5.  Irreversible inhibition of BoNT/A protease: proximity-driven reactivity contingent upon a bifunctional approach.

Authors:  Lewis D Turner; Alexander L Nielsen; Lucy Lin; Sabine Pellett; Takashi Sugane; Margaret E Olson; Eric A Johnson; Kim D Janda
Journal:  RSC Med Chem       Date:  2021-05-19

Review 6.  Toxicology and pharmacology of botulinum and tetanus neurotoxins: an update.

Authors:  Marco Pirazzini; Cesare Montecucco; Ornella Rossetto
Journal:  Arch Toxicol       Date:  2022-03-25       Impact factor: 6.168

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.